Year |
Citation |
Score |
2018 |
Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ-THC. Frontiers in Pharmacology. 9: 1084. PMID 30319418 DOI: 10.3389/Fphar.2018.01084 |
0.502 |
|
2018 |
Patton AL, Jones JO, Nord A, Eversole DW, Feazell EE, Mauldin K, Li L, Williams LD, Bai S, Channell K, Endres G, Gamette M, Moran JH. Multi-laboratory validation of a Δ9-tetrahydrocannabinol LC-MS/MS test kit designed for quantifying THC and marijuana metabolites in blood. Forensic Science and Criminology. 3. PMID 29955732 |
0.32 |
|
2018 |
Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochemical and Biophysical Research Communications. PMID 29522717 DOI: 10.1016/J.Bbrc.2018.03.028 |
0.521 |
|
2015 |
Su MK, Seely KA, Moran JH, Hoffman RS. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clinical Pharmacology and Therapeutics. 97: 562-4. PMID 25788107 DOI: 10.1002/Cpt.114 |
0.456 |
|
2014 |
Patton AL, Seely KA, Pulla S, Rusch NJ, Moran CL, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW, Moran JH. Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. Analytical Chemistry. 86: 1760-6. PMID 24354295 DOI: 10.1021/Ac4036197 |
0.528 |
|
2014 |
Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sciences. 97: 45-54. PMID 24084047 DOI: 10.1016/J.Lfs.2013.09.017 |
0.498 |
|
2013 |
Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH. Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metabolism Letters. 7: 34-8. PMID 24329780 DOI: 10.2174/187231280701131211151523 |
0.748 |
|
2013 |
Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Science International. 233: 416-22. PMID 24314548 DOI: 10.1016/J.Forsciint.2013.10.002 |
0.359 |
|
2013 |
Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH. Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Analytical Chemistry. 85: 9390-9. PMID 23987522 DOI: 10.1021/Ac4024704 |
0.77 |
|
2013 |
Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. Journal of Forensic Sciences. 58: 1676-80. PMID 23822805 DOI: 10.1111/1556-4029.12216 |
0.732 |
|
2013 |
Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicology and Applied Pharmacology. 269: 100-8. PMID 23537664 DOI: 10.1016/J.Taap.2013.03.012 |
0.45 |
|
2012 |
Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2174-84. PMID 22904561 DOI: 10.1124/Dmd.112.047530 |
0.77 |
|
2012 |
Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39: 234-43. PMID 22561602 DOI: 10.1016/J.Pnpbp.2012.04.017 |
0.427 |
|
2012 |
Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chemical Research in Toxicology. 25: 825-7. PMID 22404317 DOI: 10.1021/Tx3000472 |
0.43 |
|
2012 |
Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Biochemical Pharmacology. 83: 952-961. PMID 22266354 DOI: 10.1016/J.Bcp.2012.01.004 |
0.36 |
|
2012 |
Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH, Radominska-Pandya A. Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. The Journal of Pharmacology and Experimental Therapeutics. 340: 46-55. PMID 21972237 DOI: 10.1124/Jpet.111.184721 |
0.42 |
|
2011 |
Mock DM, Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Dawson AM, Spencer HJ, Owen SN, Boysen G, Moran JH. Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans. The Journal of Nutrition. 141: 1925-30. PMID 21918059 DOI: 10.3945/Jn.111.146126 |
0.436 |
|
2011 |
Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase i hydroxylated metabolites of the k2 synthetic cannabinoid jwh-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity Plos One. 6. PMID 21755008 DOI: 10.1371/Journal.Pone.0021917 |
0.444 |
|
2011 |
Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, James LP, Moran JH, Radominska-Pandya A. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1967-76. PMID 21746969 DOI: 10.1124/Dmd.111.040709 |
0.769 |
|
2011 |
Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Analytical Chemistry. 83: 6381-8. PMID 21740038 DOI: 10.1021/Ac201377M |
0.772 |
|
2011 |
Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, ... ... Moran JH, et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine Analytical Chemistry. 83: 4228-4236. PMID 21506519 DOI: 10.1021/Ac2005636 |
0.768 |
|
2011 |
Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Molecular Interventions. 11: 36-51. PMID 21441120 DOI: 10.1124/Mi.11.1.6 |
0.37 |
|
2011 |
Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH, Mock DM. Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. The Journal of Nutrition. 141: 353-8. PMID 21248194 DOI: 10.3945/Jn.110.135772 |
0.347 |
|
2010 |
Horvath TD, Stratton SL, Bogusiewicz A, Owen SN, Mock DM, Moran JH. Quantitative measurement of urinary excretion of 3-hydroxyisovaleryl carnitine by LC-MS/MS as an indicator of biotin status in humans Analytical Chemistry. 82: 9543-9548. PMID 21028833 DOI: 10.1021/Ac102330K |
0.434 |
|
2010 |
Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH, Mock DM. Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. The American Journal of Clinical Nutrition. 92: 1399-405. PMID 20943794 DOI: 10.3945/Ajcn.110.002543 |
0.348 |
|
2010 |
Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chemical Research in Toxicology. 23: 939-45. PMID 20429590 DOI: 10.1021/Tx1000283 |
0.481 |
|
2010 |
Horvath TD, Stratton SL, Bogusiewicz A, Pack L, Moran J, Mock DM. Quantitative measurement of plasma 3-hydroxyisovaleryl carnitine by LC-MS/MS as a novel biomarker of biotin status in humans Analytical Chemistry. 82: 4140-4144. PMID 20397702 DOI: 10.1021/Ac1003213 |
0.412 |
|
2010 |
Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metabolism Reviews. 42: 55-61. PMID 19788348 DOI: 10.3109/03602530903209395 |
0.475 |
|
2009 |
Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chemical Research in Toxicology. 22: 1239-45. PMID 19408964 DOI: 10.1021/Tx900031Z |
0.509 |
|
2009 |
Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radomińska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1496-504. PMID 19339377 DOI: 10.1124/Dmd.109.026898 |
0.485 |
|
2008 |
Miller GP, Lichti CF, Zielinska AK, Mazur A, Bratton SM, Gallus-Zawada A, Finel M, Moran JH, Radominska-Pandya A. Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 2211-8. PMID 18725508 DOI: 10.1124/Dmd.108.022863 |
0.405 |
|
2008 |
Zielinska A, Lichti CF, Bratton S, Mitchell NC, Gallus-Zawada A, Le VH, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. The Journal of Pharmacology and Experimental Therapeutics. 324: 139-48. PMID 17921187 DOI: 10.1124/Jpet.107.129858 |
0.508 |
|
2002 |
Mitchell LA, Moran JH, Grant DF. Linoleic acid, cis-epoxyoctadecenoic acids, and dihydroxyoctadecadienoic acids are toxic to Sf-21 cells in the absence of albumin. Toxicology Letters. 126: 187-96. PMID 11814707 DOI: 10.1016/S0378-4274(01)00463-5 |
0.343 |
|
2001 |
Moran JH, Mitchell LA, Grant DF. Linoleic acid prevents chloride influx and cellular lysis in rabbit renal proximal tubules exposed to mitochondrial toxicants. Toxicology and Applied Pharmacology. 176: 153-161. PMID 11714247 DOI: 10.1006/Taap.2001.9270 |
0.319 |
|
2001 |
Moran JH, Mon T, Hendrickson TL, Mitchell LA, Grant DF. Defining mechanisms of toxicity for linoleic acid monoepoxides and diols in Sf-21 cells. Chemical Research in Toxicology. 14: 431-7. PMID 11304132 DOI: 10.1021/Tx000200O |
0.338 |
|
2001 |
Moran JH, Nowak G, Grant DF. Analysis of the toxic effects of linoleic acid, 12,13-cis-epoxyoctadecenoic acid, and 12,13-dihydroxyoctadecenoic acid in rabbit renal cortical mitochondria. Toxicology and Applied Pharmacology. 172: 150-161. PMID 11298501 DOI: 10.1006/Taap.2001.9149 |
0.316 |
|
2000 |
Moran JH, Mitchell LA, Bradbury JA, Qu W, Zeldin DC, Schnellmann RG, Grant DF. Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicology and Applied Pharmacology. 168: 268-79. PMID 11042099 DOI: 10.1006/Taap.2000.9053 |
0.352 |
|
1997 |
Moran JH, Weise R, Schnellmann RG, Freeman JP, Grant DF. Cytotoxicity of linoleic acid diols to renal proximal tubular cells. Toxicology and Applied Pharmacology. 146: 53-9. PMID 9299596 DOI: 10.1006/Taap.1997.8197 |
0.335 |
|
Show low-probability matches. |